Angene Chemical
Draw
|
Currency :
Home Products

AG0039GV

1051375-16-6 | (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide

Chemical structure of (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, CAS 1051375-16-6
AG0039GV
sdsSDS
sdsCOA
TIP This product is typically in stock.Please contact us for quotation.
Request For Quotation

CAS Number 1051375-16-6
Catalog Number AG0039GV
Chemical Name (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
EC Number 809-888-1
IUPAC Name (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide
InChI InChI=1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1
InChI Key RHWKPHLQXYSBKR-BMIGLBTASA-N
MDL Number MFCD20488027
Molecular Formula C20H19F2N3O5
Molecular Weight 419.3788
SMILES FC1=C(C=CC(=C1)F)CNC(=O)C=1C(C(=C2N(C[C@@H]3OCC[C@H](N3C2=O)C)C1)O)=O
UNII DKO1W9H7M1
Synonyms
(4R,9aS)-5-hydroxy-2-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid- 2,4 difluorobenzylamide, dolutegravir, dolutegravir sodium, dolutegravir sodium monohydrate, GSK 1349572A, GSK-1349572, GSK1349572A, S-GSK1349572, Tivicay, Dolutegravir, 1051375-16-6, GSK1349572, Tivicay, S/GSK1349572, Dolutegravir (GSK1349572), GSK 1349572, S-349572, GSK-1349572, UNII-DKO1W9H7M1, (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide, CHEBI:76010, S-GSK1349572, DKO1W9H7M1, (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, Tivicay (TN), Dolutegravir Sodium ( API), Dolutegravir [USAN:INN], Soltegravir, HSDB 8152, DLU, Dolutegravir (USAN), 3s3m, 3s3n, 3s3o, (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[[?]:[?]]pyrazino[[?]][1,3]oxazine-9-carboxamide, cc-13, SCHEMBL82071, MLS006011137, GTPL7365, QCR-34, CHEMBL1229211, C20H19F2N3O5, RHWKPHLQXYSBKR-BMIGLBTASA-N, AOB87150, EX-A1695, methyl-9,12-dioxo-4-oxa-1,8-, ABP000915, BDBM50062551, MFCD20488027, s2667, ZINC58581064, AKOS025396657, S/GSK-1349572, API0013713, BCP9000620, CS-0454, DB08930, PB33506, RL00238, NCGC00346629-01, AC-28371, BC638753, HY-13238, SC-85939, SMR004702915, AB0033823, A4074, FT-0701265, X7595, S/GSK1349572,GSK1349572, D10066, Q-4931, J-501471, diazatricyclo[8.4.0.0?,?]tetradeca-10,13-diene-13-, (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-, (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0^{3,8}]tetradeca-10,13-diene-13-carboxamide, (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-a]pyrido[1,2-d]pyrazine-9-carboxamide, (4R,12aS)-N-(2,4-Difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-9-carboxamide, (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1,2:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1 ,3]oxazine-9-carboxamide, (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[5,6]pyrazino[2,6-b][1,3]oxazine-9-carboxamide, carboxamide, Cabotegravir, Dolutegravir [USAN], DOLUTEGRAVIR SODIUM, D00YZD, D0W0TW, ACN-041355, C20-H19-F2-N3-O5, 1062161-90-3, WYE687, WYE 687, 2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide, N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-, DTG, 1051375-19-9, 1172581-47-3, 900515-16-4, Dolutegravi;GSK1349572;(4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide;S/GSK1349572(GSK1349572);Dolutegravir;GSK1349572(dolutegravir);S/GSK1349572,

Related Research Chemicals

    CERTIFICATE OF ANALYSIS
    Chemical Name: Batch Number:
    Chemical Structure: CAS Registry No:
    		Product ID:
    Manufacture Date:
    Storage Temperature:
    Formula:
    Molecular Weight:
    Quantity:
    Analysis Data:
    Test: Result:
    Conclusion: The above product meets the specifications of Angene.
    Analyst:Chase
    Date:
    Reviewed by:Jessie
    Date:
    Angene International Limited